We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Medifast's Trilivy Launch Unlock a New Growth Chapter?
Read MoreHide Full Article
Key Takeaways
Medifast launched Trilivy to expand beyond traditional weight management into broader metabolic health.
Trilivy combines nutrition, personalized coaching and behavior-based support across three structured phases.
Coach productivity and referral-driven client acquisition improved in the first quarter of 2026.
Medifast, Inc. (MED - Free Report) has launched Trilivy, a science-backed metabolic health system that expands the company’s focus beyond traditional weight management. The platform combines nutritional products, personalized coaching and behavior-based support while introducing newly formulated meal replacements featuring proprietary ingredient technology intended to support metabolic health.
The launch marks an important strategic shift as GLP-1 medications continue to reshape the weight-loss market and pressure demand for conventional programs. Trilivy emphasizes broader metabolic health, including visceral-fat reduction, lean-mass preservation, healthy metabolism and sustainable lifestyle improvement. This positioning could help MED appeal to consumers seeking longer-term wellness support, including those looking for alternatives or complements to medication-based weight-loss solutions.
Trilivy also builds on Medifast’s established coach-led model. Its three-phase system — Reset, Refine and Renew — integrates nutritional products, individualized support and healthy habits into a structured customer journey. This approach may strengthen the company’s differentiation from product-only competitors by combining science-backed nutrition with accountability and behavioral guidance.
The launch arrives as some operating indicators are beginning to improve. In the first quarter of 2026, coach productivity increased for a second consecutive time, while referral-driven client acquisition gained momentum. Coaches participating in the referral program generated higher acquisition rates than nonparticipants, suggesting that efforts to improve field engagement are yielding encouraging early results.
Overall, Trilivy gives Medifast a clearer framework for repositioning its business around metabolic health. Successful customer adoption, stronger coach participation and improved engagement could help stabilize revenues and support profitability over time, potentially opening a new growth chapter for the Zacks Rank #1 (Strong Buy) company. You can see the complete list of today’s Zacks #1 Rank stocks here.
MED Stock Price Performance, Valuation & Estimates
Shares of Medifast have tumbled 25.6% over the past year compared with the industry’s decline of 21.7%.
MED Price Performance Versus Industry
Image Source: Zacks Investment Research
From a valuation standpoint, Medifast trades at a forward price-to-sales ratio of 0.42, lower than the industry’s average of 0.79.
MED Valuation Compared to Industry
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal-year earnings per share implies a year-over-year decline of 140.2%, while the consensus mark for the next year’s EPS suggests growth of 4.1%.
Other Stocks to Consider
United Natural Foods, Inc. (UNFI - Free Report) , a major food wholesaler serving grocery retailers, currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for United Natural’s current and next fiscal-year earnings per share suggests a year-over-year increase of 254.9% and 21.4%, respectively. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.
Mama's Creations, Inc. (MAMA - Free Report) , a maker of refrigerated prepared foods for retail and foodservice, carries a Zacks Rank #2 (Buy) at present.
The Zacks Consensus Estimate for Mama's Creations’ current and next fiscal-year EPS suggests growth of 73.3% and 46.2%, respectively, from the prior-year reported levels. MAMA delivered a trailing four-quarter earnings surprise of 129.2%, on average.
Hormel Foods Corporation (HRL - Free Report) , a global branded food company offering meat, protein and packaged food products, carries a Zacks Rank #2.
The Zacks Consensus Estimate for Hormel Foods’ current and next fiscal-year EPS calls for a year-over-year jump of 9.5% and 3.5%, respectively. HRL delivered a trailing four-quarter earnings surprise of 3.2%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Will Medifast's Trilivy Launch Unlock a New Growth Chapter?
Key Takeaways
Medifast, Inc. (MED - Free Report) has launched Trilivy, a science-backed metabolic health system that expands the company’s focus beyond traditional weight management. The platform combines nutritional products, personalized coaching and behavior-based support while introducing newly formulated meal replacements featuring proprietary ingredient technology intended to support metabolic health.
The launch marks an important strategic shift as GLP-1 medications continue to reshape the weight-loss market and pressure demand for conventional programs. Trilivy emphasizes broader metabolic health, including visceral-fat reduction, lean-mass preservation, healthy metabolism and sustainable lifestyle improvement. This positioning could help MED appeal to consumers seeking longer-term wellness support, including those looking for alternatives or complements to medication-based weight-loss solutions.
Trilivy also builds on Medifast’s established coach-led model. Its three-phase system — Reset, Refine and Renew — integrates nutritional products, individualized support and healthy habits into a structured customer journey. This approach may strengthen the company’s differentiation from product-only competitors by combining science-backed nutrition with accountability and behavioral guidance.
The launch arrives as some operating indicators are beginning to improve. In the first quarter of 2026, coach productivity increased for a second consecutive time, while referral-driven client acquisition gained momentum. Coaches participating in the referral program generated higher acquisition rates than nonparticipants, suggesting that efforts to improve field engagement are yielding encouraging early results.
Overall, Trilivy gives Medifast a clearer framework for repositioning its business around metabolic health. Successful customer adoption, stronger coach participation and improved engagement could help stabilize revenues and support profitability over time, potentially opening a new growth chapter for the Zacks Rank #1 (Strong Buy) company. You can see the complete list of today’s Zacks #1 Rank stocks here.
MED Stock Price Performance, Valuation & Estimates
Shares of Medifast have tumbled 25.6% over the past year compared with the industry’s decline of 21.7%.
MED Price Performance Versus Industry
Image Source: Zacks Investment Research
From a valuation standpoint, Medifast trades at a forward price-to-sales ratio of 0.42, lower than the industry’s average of 0.79.
MED Valuation Compared to Industry
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal-year earnings per share implies a year-over-year decline of 140.2%, while the consensus mark for the next year’s EPS suggests growth of 4.1%.
Other Stocks to Consider
United Natural Foods, Inc. (UNFI - Free Report) , a major food wholesaler serving grocery retailers, currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for United Natural’s current and next fiscal-year earnings per share suggests a year-over-year increase of 254.9% and 21.4%, respectively. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.
Mama's Creations, Inc. (MAMA - Free Report) , a maker of refrigerated prepared foods for retail and foodservice, carries a Zacks Rank #2 (Buy) at present.
The Zacks Consensus Estimate for Mama's Creations’ current and next fiscal-year EPS suggests growth of 73.3% and 46.2%, respectively, from the prior-year reported levels. MAMA delivered a trailing four-quarter earnings surprise of 129.2%, on average.
Hormel Foods Corporation (HRL - Free Report) , a global branded food company offering meat, protein and packaged food products, carries a Zacks Rank #2.
The Zacks Consensus Estimate for Hormel Foods’ current and next fiscal-year EPS calls for a year-over-year jump of 9.5% and 3.5%, respectively. HRL delivered a trailing four-quarter earnings surprise of 3.2%, on average.